Gm-csf

Description: mGMP Recombinant Human GM-CSF produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 127 amino acids and having a molecular mass of 14477 Dalton. rHuGM-CSF is purified by proprietary chromatographic techniques. Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder. Formulation & Packaging... : The protein was lyophilized after extensive dialysis against 2mM sodium phosphate buffer pH= 7.40.1. Stability: Lyophilized mGMPrHuGM-CSF although stable at room temperature, should be stored desiccated below 0C. Reconstituted rHuGM-CSF is best stored refrigerated at 4C. Purity: Greater than 99.0% as determined by: (Limit of acceptance:98.0%. No more than 2% total impurities; no single impurity greater than 1%) Amino acid sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Pro-Ala-Arg-Ser, conforming the sequence of native human GM-CSF. N-terminal methionine has been completely removed enzymatically. Biological Activity: mGMPrHuGM-CSF is fully biologically active when compared to standard.The ED50 as determined by the dose-dependant stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line) is 0.1 ng/ml, corresponding to a Specific Activity of 9x106 IU/mg or 2 800 000 IU/ vial of 300 ug Endotoxin: Less than 0.1 ng/g (IEU/g) of mGMPrHuGM-CSF. coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE Usage: This material is offered by Gentaur for research, laboratory or further manufacturing purposes adn DC culture Hematopoietic cell lines K562, human erythroleukemia cell line (HEL), HL60, TF-1, Jurkat, Daudi, CEM, and ML1 (ATCC, Manassas, VA, USA) were cultured in the presence of 10% fetal bovine serum (FBS) (Euroclone, Milano, Italy) in Iscove's modified Dulbecco's medium (IMDM) or RPMI (Euroclone, Milano Italy) and 5% CO2 in a humidified atmosphere of 5% O2 in air at 37C. TF-1 required the addition of 10 ng/ml of human granulocyte-macrophage ...Read More